Nanoparticle-mediated angiotensin-(1-9) drug delivery for the treatment of cardiac hypertrophy

Ang-(1-9) peptide is a bioactive vasodilator peptide that prevents cardiomyocyte hypertrophy in vitro and in vivo as well as lowers blood pressure and pathological cardiovascular remodeling; however, it has a reduced half-life in circulation, requiring a suitable carrier for its delivery. In this work, hybrid nanoparticles composed of polymeric nanoparticles (pNPs) based on Eudragit® E/Alginate (EE/Alg), and gold nanospheres (AuNS), were developed to evaluate their encapsulation capacity and release of Ang-(1-9) under different experimental conditions. Hybrid pNPs were characterized by dynamic light scattering, zeta potential, transmission and scanning electron microscopy, size distribution, and concentration by nanoparticle tracking analysis. Nanometric pNPs, with good polydispersity index and colloidally stable, produced high association efficiency of Ang-(1-9) and controlled release. Finally, the treatment of neonatal cardiomyocytes in culture with EE/Alg/AuNS 2% + Ang-(1-9) 20% pNPs decreased the area and perimeter, demonstrating efficacy in preventing norepinephrine-induced cardiomyocyte hypertrophy. On the other hand, the incorporation of AuNS did not cause negative effects either on the cytotoxicity or on the association capacity of Ang-(1-9), suggesting that the hybrid carrier EE/Alg/AuNS pNPs could be used for the delivery of Ang-(1-9) in the treatment of cardiovascular hypertrophy. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Notas

Indexación: Scopus

Palabras clave

Angiotensin-(1-9), Cardiac hypertrophy, Gold nanoparticles, Peptide delivery, Polymeric nanoparticles

Citación

Pharmaceutics Volume 13, Issue 62021June Article number 822

DOI

10.3390/pharmaceutics13060822

URI

https://repositorio.unab.cl/xmlui/handle/ria/53405

Colecciones

Fac.CV - Artículos de Revista

Página completa del ítem